Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mirum Pharmaceuticals, Inc.
The study consists of 3 study arms. Approximately 80 participants will be randomized 2:1:1 to one of the following treatment arms:
Arm 1: Participants will receive brelovitug 300 mg subcutaneously once weekly for 96 weeks.
Arm 2: Participants will receive brelovitug 900 mg subcutaneously once every 4 weeks for 96 weeks.
Arm 3: Participants will attend study clinic visits and delay treatment with brelovitug for 12 weeks. At Week 12, participants will receive brelovitug 300 mg subcutaneously once weekly for 96 weeks.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Willing and able to provide written informed consent
2. Chronic HDV infection
3. HDV RNA \>500 IU/mL at Screening
4. ALT \>ULN at Screening
5. Willing to take or already taking HBV nucleos(t)ide therapy.
You may not be if
1. Pregnant or nursing females
2. Unwilling to comply with contraception requirements during the study
3. Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy
